Fig. 5From: High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospective studyReceiver operating characteristics (ROC) curves for baseline mutations in tumor and ctDNA (A) and longitudinal measurements (B) in predicting 6-month overall survival (OS; left) and progression-free survival (PFS; right). AUC, area under the curveBack to article page